In cancer immunotherapy, a growing body of work has shown that fine-tuning T cell metabolism—for example, by moderately restricting glycolysis to favor memory-like differentiation, enhancing fatty acid oxidation, or using “metabolic immunoengineering” strategies—can significantly augment the efficacy and durability of CD8+ T cell–based therapies and immune checkpoint blockade [96,99,100,101]. Here, CD8A is linked to cancer.